Drugs / Disitamb Vedotin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06001086 | Nov 2023 → Aug 2026 overdue | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Disitamb Vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06001086 ↗ |
| Route | Intravenous | “Disitamb Vedotin: 2 mg/kg，ivgtt，d1,14/28day/cycle” NCT06001086 ↗ |